Mobile
Recherche simple
Recherche avancée
Recherche multicritère
Qui sommes-nous ?
Connexion
Inscription
French
English
Kusajili – Centralise les essais cliniques mondiaux
Résultat
de votre recherche par promoteur : Merck & Co., Inc
Femme et Homme Max 99 ans
Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc
MAJ Il y a 5 ans
Pembrolizumab or placebo in combination with chemoradiation (CRT) in subjects with locally advanced HNSCC
To compare Event-free survival (EFS) per RECIST (Response Evaluation Criteria in Solid Tumors) 1.1 by blinded independent central review (BICR) in subjects treated with pembrolizumab in combination wi...
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
unknown
Plus d'informations
Femme Max 99 ans
Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc
MAJ Il y a 5 ans
A Six Month Phase II/III, Randomized, Double-Blind, Placebo-Controlled Clinical Trial to Evaluate the Safety, Tolerabitlity, and Efficacy of Telcagepant (MK-0974) for prevention of Menstrually Related Migraine in Female Patients with Episodic Migraine
1. To evaluate the efficacy of telcagepant 140 mg once daily for 7-days per month compared to placebo for the prevention of migraine during the study period in female patients with menstruelly relate...
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
Essai clos aux inclusions
Plus d'informations
Femme et Homme Max 99 ans
Merck & Co., Inc
MAJ Il y a 5 ans
An Open Label, Randomized Phase I/IIa Trial Evaluating MK-0646 in Combination With Erlotinib (TARCEVA™) for Patients With Recurrent Non-Small Cell Lung Cancer
Phase I: To determine the safety and tolerability of erlotinib in combination with MK-0646 in patients with recurrent NSCLC. Phase II: To evaluate the effect of the combination of erlotinib and MK-064...
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
Essai clos aux inclusions
Plus d'informations
Femme et Homme Max 99 ans
Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc
MAJ Il y a 5 ans
Pediatric study to evaluate the appropriate dose for aprepitant in pediatric patients undergoing surgery. Estudio pediatrico para evaluar la dosis apropiada de aprepitant en pacientes pediátricos para la prevención de las náuseas y los vómitos postoperatorios
To estimate post-operative aprepitant plasma concentration profiles and pharmacokinetic parameters by population analysis including historical data (e.g. Cmax, Tmax, AUC0-?, t1/2, CL/F) in Dose 1, 2, ...
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
Essai clos aux inclusions
Plus d'informations
Femme et Homme Max 99 ans
Merck & Co., Inc
MAJ Il y a 5 ans
Assessment of Safety and Single-Dose Pharmacokinetics in Children
To assess the safety and tolerability of single doses of rizatriptan ODT in pediatric migraineurs ages 6 - 17 years. To obtain preliminary plasma pharmacokinetic data (e.g., AUC, Cmax, Tmax, and termi...
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
Plus d'informations
Femme et Homme Max 99 ans
Merck & Co., Inc
MAJ Il y a 5 ans
A Phase III Randomized, Active-Comparator (Pioglitazone) Controlled Clinical Trial to Study the Efficacy and Safety of MK-0431A (A Fixed-Dose Combination Tablet of Sitagliptin and Metformin) in Patients With Type 2 Diabetes Mellitus
HbA1c after 32 weeks; safety and tolerability
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
Essai clos aux inclusions
Plus d'informations
Femme Max 99 ans
Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc
MAJ Il y a 5 ans
Trial 1 to Assess MK-8342B Treatment Efficacy-Safety in Dysmenorrhea plus Extension
1) Objective: To evaluate the efficacy of the ENG-E2 vaginal ring relative to placebo in the treatment of dysmenorrhea at Treatment Cycle 2. 2) Objective: To assess the safety and tolerability of the...
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
Essai clos aux inclusions
Plus d'informations
Femme Max 99 ans
Merck & Co., Inc
MAJ Il y a 5 ans
A Randomized, International, Double-Blinded (With In-House Blinding), Controlled With GARDASIL™, Tolerability, Immunogenicity, and Efficacy Study of a Second Generation Human Papillomavirus (HPV) L1 Virus-Like Particle (VLP) Vaccine Administered to 16- to 26-Year-Old Women
To evaluate the tolerability of the octavalent HPV L1 VLP vaccine when administered to 16- to 26-year-old women. To demonstrate that administration of octavalent HPV L1 VLP vaccine will reduce the c...
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
Essai clos aux inclusions
Plus d'informations
Femme et Homme Max 99 ans
Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc
MAJ Il y a 5 ans
Pembrolizumab vs Chemotherapy in Microsatellite Instability-High or Mismatch Repair Deficient Stage IV Colorectal Cancer
To compare Progression Free Survival (PFS) per RECIST 1.1 by central imaging vendor in subjects with first line (1L) stage IV MSI-H or dMMR CRC treated with pembrolizumab versus SOC chemotherapies.
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
unknown
Plus d'informations
Femme et Homme Max 99 ans
Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc
MAJ Il y a 5 ans
A Phase 3 study in Patients with Type 2 Diabetes Mellitus
To assess the impact of MK-3102 25 mg q.w. on time to confirmed CV outcomes as measured by the time to first event in the CV composite endpoint of CV-related death, nonfatal MI, nonfatal stroke, or un...
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
Essai clos aux inclusions
Plus d'informations
Précédent
11
12
13
14
15
16
17
18
19
20
Suivant